Trump picks policy expert Overton to head US Food and Drug Administration

Overton's selection to lead the FDA signals the administration's intention to pursue significant changes in how the agency regulates pharmaceuticals, medical devices, and food safety. Her background in policy research at a Washington think tank has positioned her within conservative circles focused on regulatory reform.

The nomination is expected to face scrutiny from public health advocates and congressional Democrats, who may question her experience in overseeing the sprawling federal health regulator. Supporters of Trump's agenda have argued that such appointments are necessary to streamline government operations and reduce regulatory burdens on industry.

The FDA, which oversees products worth hundreds of billions of dollars annually, has long been a focal point for those seeking to accelerate drug approvals and reduce compliance requirements for manufacturers. Overton would assume leadership of the agency amid ongoing debates about balancing innovation with consumer safety protections.

The nomination requires Senate confirmation. The appointment process is likely to highlight broader tensions between those advocating for lighter regulation and those emphasizing the FDA's public health mission.